World Health Organization Issues Concern Over Critical Scarcity of Weight-Loss Injections

Under 10% of patients who could benefit from weight-loss injections including Wegovy are able to get them, warns the WHO as it publishes its initial advice on the medications.

Given over a billion people worldwide currently classified as obese, it is urging more widespread and fairer availability to these injectable treatments.

Per forecasts, over two billion could be obese by 2030 if no action is taken.

"Our latest guidelines acknowledges that excess weight is a chronic disease that can be treated with thorough and lifelong treatment," stated WHO director-general Tedros Adhanom Ghebreyesus.

High costs, limited production capacity, and supply-chain constraints are key obstacles to widespread access to the jabs that can assist patients in reducing considerable weight, explains the organization.

Skinny Jab Shortage

Even under the current best projected scenario, the production of such drugs would only suffice for about 100 million people – fewer than 10% of eligible patients, as stated by the WHO.

The recommendation urges nations and manufacturers to increase availability, through strategies such as patent sharing.

A patent on a key compound – the core ingredient of a leading brand – is set to lapse in a number of nations in 2026.

The Way Obesity Jabs Work

These medications replicate a body's own hormone to reduce digestion speed, suppress the appetite and boost satiety so users eat less.

People commonly begin shedding pounds in the initial weeks of starting on the once-weekly jabs.

Studies indicates patients may put most of the weight back on within a year of halting the drug, as their usual appetite come back.

To be above a healthy weight increases your chance for developing medical conditions, including diabetes, heart disease, brain attack, and some cancers.

Obesity affects individuals in all nations and was linked to millions of fatalities worldwide in 2024, as per the health agency.